MedTrace Logo

Voice Treatment for Parkinson's Disease

NCT03700684 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-05-30

Study results available
· View outcomes & findings →

Summary

This study addresses several issues related to the clinical management of speech and voice disorders associated with Parkinson's disease. Two behavioral treatment programs, Lee Silverman Voice Treatment and SpeechVive, are assessed in their ability to improve communication in persons with Parkinson's disease.

Conditions

  • Idiopathic Parkinson Disease

Interventions

BEHAVIORAL

Lee Silverman Voice Treatment

Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.

DEVICE

SpeechVive

Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.

BEHAVIORAL

Control

Persons assigned to the non-treatment control group will not participate in voice treatment.

Sponsors & Collaborators

  • National Institute on Deafness and Other Communication Disorders (NIDCD)

    collaborator NIH

  • Purdue University

    collaborator OTHER

  • University of Massachusetts, Amherst

    lead OTHER

Principal Investigators

  • Kelly Richardson, Ph.D. · University of Massachusetts, Amherst

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-19
Primary Completion
2020-03-15
Completion
2022-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03700684 on ClinicalTrials.gov